Luxembourg-Bertrange, January 17th, 2019 – Vesalius Biocapital III, the specialist life sciences venture capital investor, announces an investment of €30 million by the European Investment Fund (EIF). This secures commitments of €110 million to date. Until the final closing, scheduled for end April 2019, Vesalius Biocapital III will accept new investors on a “rolling closing” basis. The fund will invest in later-stage European life sciences companies, providing capital to support their development. Vesalius Biocapital III has executed three investments to date.